Literature DB >> 15946584

New therapeutic options for mesothelioma.

Ranjit Kumar Goudar1.   

Abstract

Malignant pleural mesothelioma is an aggressive thoracic tumor that is often refractory to chemotherapy and radiotherapy, making long-term survival a difficult goal. Although multimodality therapies, including cytoreductive surgery, chemotherapy, and radiotherapy, have been tested, their survival benefit is unclear. Recently, novel cytotoxic agents such as pemetrexed have shown promise in the treatment of malignant pleural mesothelioma, and in early trials new small-molecule agents targeted to the specific biochemical properties of this tumor have shown promise.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15946584     DOI： 10.1007/s11912-005-0048-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.945


  39 in total

1.  Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma: is it safe?

Authors:  Güngör Utkan; Bülent Yalçin; Abdullah Büyükçelik; Samet Yalçin
Journal:  J Clin Oncol       Date:  2005-01-20       Impact factor: 44.544

2.  Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients.

Authors:  L de Graaf-Strukowska; J van der Zee; W van Putten; S Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-02-01       Impact factor: 7.038

3.  A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.

Authors:  V W Rusch; K Rosenzweig; E Venkatraman; L Leon; A Raben; L Harrison; M S Bains; R J Downey; R J Ginsberg
Journal:  J Thorac Cardiovasc Surg       Date:  2001-10       Impact factor: 5.209

Review 4.  Innovative therapies: photodynamic therapy.

Authors:  Evelio Rodriguez; Paul Baas; Joseph S Friedberg
Journal:  Thorac Surg Clin       Date:  2004-11       Impact factor: 1.750

5.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Authors:  Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

Review 6.  FDA drug approval summaries: pemetrexed (Alimta).

Authors:  Maitreyee Hazarika; Robert M White; John R Johnson; Richard Pazdur
Journal:  Oncologist       Date:  2004

Review 7.  Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.

Authors:  Hedy L Kindler
Journal:  Lung Cancer       Date:  2004-08       Impact factor: 5.705

8.  Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma.

Authors:  Terry T Lee; Darcie L Everett; Hui-Kuo G Shu; Thierry M Jahan; Mack Roach; Joycelyn L Speight; Robert B Cameron; Theodore L Phillips; Albert Chan; David M Jablons
Journal:  J Thorac Cardiovasc Surg       Date:  2002-12       Impact factor: 5.209

9.  Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.

Authors:  Bertram Price; Adam Ware
Journal:  Am J Epidemiol       Date:  2004-01-15       Impact factor: 4.897

10.  Elevated serum cytokine levels in mesothelioma patients who have undergone pleurectomy or extrapleural pneumonectomy and adjuvant intraoperative photodynamic therapy.

Authors:  Sue S Yom; Theresa M Busch; Joseph S Friedberg; E Paul Wileyto; Deborah Smith; Eli Glatstein; Stephen M Hahn
Journal:  Photochem Photobiol       Date:  2003-07       Impact factor: 3.421
View more
  7 in total

1.  Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis.

Authors:  Ying Wang; Arun K Rishi; Wenjuan Wu; Lisa Polin; Sunita Sharma; Edi Levi; Steven Albelda; Harvey I Pass; Anil Wali
Journal:  Mol Cell Biochem       Date:  2011-05-19       Impact factor: 3.396

2.  Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines.

Authors:  Ying Wang; Arun K Rishi; Vineshkumar T Puliyappadamba; Sunita Sharma; Huanjie Yang; Adi Tarca; Q Ping Dou; Fulvio Lonardo; John C Ruckdeschel; Harvey I Pass; Anil Wali
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-04       Impact factor: 3.333

3.  Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells.

Authors:  R Eguchi; T Nakano; I Wakabayashi
Journal:  Oncogene       Date:  2016-06-27       Impact factor: 9.867

4.  Proteasome Inhibitor MG132 Induces Apoptosis and Inhibits Invasion of Human Malignant Pleural Mesothelioma Cells.

Authors:  Bao-Zhu Yuan; Joshua A Chapman; Steven H Reynolds
Journal:  Transl Oncol       Date:  2008-09       Impact factor: 4.243

Review 5.  Management options for malignant pleural mesothelioma: clinical and cost considerations.

Authors:  Ranjit K Goudar
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  TRAIL and proteasome inhibitors combination induces a robust apoptosis in human malignant pleural mesothelioma cells through Mcl-1 and Akt protein cleavages.

Authors:  Bao-Zhu Yuan; Joshua Chapman; Min Ding; Junzhi Wang; Binghua Jiang; Yon Rojanasakul; Steven H Reynolds
Journal:  BMC Cancer       Date:  2013-03-22       Impact factor: 4.430

7.  Proteasome stress sensitizes malignant pleural mesothelioma cells to bortezomib-induced apoptosis.

Authors:  Fulvia Cerruti; Genny Jocollè; Chiara Salio; Laura Oliva; Luca Paglietti; Beatrice Alessandria; Silvia Mioletti; Giovanni Donati; Gianmauro Numico; Simone Cenci; Paolo Cascio
Journal:  Sci Rep       Date:  2017-12-15       Impact factor: 4.379
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.